AMENDED AND RESTATED] EMPLOYMENT AGREEMENTEmployment Agreement • February 24th, 2016 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations • Massachusetts
This [Amended and Restated] Employment Agreement (the “Agreement”) is entered into as of [Date] (the “Effective Date”) by and between AMAG Pharmaceuticals, Inc., a Delaware corporation with offices at 1100 Winter Street, Waltham, MA 02451 (together with its subsidiaries and affiliates, the “Company”), and [Executive Name] of [Address] (“you”).
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORSRestricted Stock Unit Award Agreement • February 24th, 2016 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
Pursuant to the AMAG Pharmaceuticals, Inc. Third Amended and Restated 2007 Equity Incentive Plan as amended through the date hereof (the “Plan”), AMAG Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.01 per share (the “Stock”) of the Company.
AMAG PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT AWARD AGREEMENTRestricted Stock Unit Award Agreement • February 24th, 2016 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
AMAG Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above, as an inducement grant made pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.01 per share (the “Stock”) of the Company. For the avoidance of doubt, this Award is not issued under the Company’s Third Amended and Restated 2007 Equity Incentive Plan, as amended through the date hereof (the “Plan”) and does not reduce the share reserve under the Plan. However, for purposes of interpreting the applicable provisions of this Award, the terms and conditions of the Plan (other than those applicable to the share reserve) shall govern and apply to this Award as if such Award had actually been issued under the Plan.
Amendment No. 3Commercial Supply Agreement • February 24th, 2016 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
This Amendment No. 3 (“Amendment”), effective as of August 24, 2015 (the “Effective Date”), entered into by and between (i) AMAG Pharmaceuticals, Inc. (“AMAG” or the “Company”) and (ii) Sigma-Aldrich, Inc. (“SAFC”), amends that certain Commercial Supply Agreement between AMAG and SAFC dated August 29, 2012 (the “Commercial Supply Agreement”), as amended October 3, 2013 (“Amendment No. 1”) and as amended March 31, 2015 (“Amendment No. 2”), and collectively with the Commercial Supply Agreement, the (“Agreement”). Capitalized terms used but not defined in this Amendment will have the meanings given them in the Agreement.
THIRD AMENDMENT TO LEASELease • February 24th, 2016 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
THIRD AMENDMENT TO LEASE dated as of this 7th day of December, 2015 (the “Effective Date”), by and between BP BAY COLONY LLC, a Delaware limited liability company (“Landlord”) and AMAG PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEESRestricted Stock Unit Award Agreement • February 24th, 2016 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
Pursuant to the AMAG Pharmaceuticals, Inc. Third Amended and Restated 2007 Equity Incentive Plan/Lumara Health Inc. Amended and Restated 2013 Incentive Compensation Plan, as amended through the date hereof (the “Plan”), AMAG Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.01 per share (the “Stock”) of the Company.
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • February 24th, 2016 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This Development and License Agreement ("Agreement") is made and entered into as of the 30th day of September, 2014 (the "Effective Date") by and between Antares Pharma, Inc., a Delaware corporation, with offices located at 100 Princeton South, Suite 300, Ewing, NJ 08628 ("Antares"), and Lumara Health Inc., a Delaware corporation, with a corporate address at 16640 Chesterfield Grove Road, Suite 200, Chesterfield, MO 63005 ("Lumara"). Antares and Lumara are sometimes referred to herein individually as a "Party" and collectively as the "Parties", and references to "Antares" and "Lumara" shall include their respective Affiliates.
SECOND AMENDMENT TO LEASELease • February 24th, 2016 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
SECOND AMENDMENT TO LEASE dated as of this 4th day of December, 2015 (the "Effective Date"), by and between BP BAY COLONY LLC, a Delaware limited liability company ("Landlord"), and AMAG PHARMACEUTICALS, INC., a Delaware corporation ("Tenant").
